The manuscript, published in Clinical Pharmacology and Therapeutics, presents principles for validating proarrhythmia risk prediction models for regulatory use, based on the example of the CiPA paradigm, and it constitutes the results of a combined effort across regulators, industry and academia.
Elisa Passini, Cristian Trovato, Francesca Margara and Polina Mamoshina will present their research at the upcoming Safety Pharmacology Society Annual Meeting in Barcelona, together with many of our collaborators. Look out for our posters and presentations!
Listen to Elisa Passini's interview for "The Naked Scientists" podcast about computer simulations of the human heart:
The Virtual Phisiological Human conference 2018 is taking place in Zaragoza, 5-7 September, 2018.
One of the main challenges in the field of Computational Systems Biomedicine is to merge these fields together. The Physiome and Virtual Physiological Human aim to deliver computational modelling frameworks for integrating every level in human biology – one that links genes, proteins, cells and organs to the whole body. Ultimately, the goal of the VPH/Physiome Project is to piece together the complete virtual physiological human: a personalised, 3-D model of an individual’s unique physiological make-up.
Blanca Rodriguez is a keynote speaker at the Conference. Ana Minchole is giving a talk on “Clinical MRI-based multiscale computational models of heart and torso to investigate the role of anatomy on ECG” and Hector Martinez is presenting the research on “Arrhythmogenic mechanisms in silent acute myocardial ischemia”.
The Gordon conference on Contemporary Advances and Challenges in Drug Safety Assessment is held on June 10 - 15, 2018.
Delivering safe and effective drugs remains a major challenge in biomedical science. To address this important challenge, the Drug Safety GRC program is designed to span safety science across the development pipeline from target selection and complex systems biology through the patient experience.
The computational Cardiovascular Science team took this opportunity to present the latest research on in silico drug trials.